Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer

<p>Pathway enrichment analysis of genes associated with differentially methylated CpG sites in HER3+ vs. HER3-</p>

Shranjeno v:

Bibliografske podrobnosti
Glavni avtor:	Erwin Tomasich (15052256) (author)
Drugi avtorji:	Ariane Steindl (15022655) (author), Christina Paiato (15360180) (author), Teresa Hatziioannou (15052262) (author), Markus Kleinberger (15360183) (author), Luzia Berchtold (15360186) (author), Rainer Puhr (15052253) (author), Johannes A. Hainfellner (15360189) (author), Leonhard Müllauer (15118769) (author), Georg Widhalm (15052268) (author), Franziska Eckert (15360192) (author), Rupert Bartsch (15360195) (author), Gerwin Heller (15052250) (author), Matthias Preusser (15017558) (author), Anna Sophie Berghoff (15360198) (author)
Izdano:	2025
Teme:	Cancer Tumor Biology Therapeutic Research and Development Clinical Research and Trials Biological Agents & Therapies Antibody-drug conjugates Breast Cancer Clinical-Stage Research Drug Targets Cell surface receptor drug targets Lung Cancer Progression, Invasion & Metastasis Metastasis
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Izdano: (2025)

Supplementary Table S1 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Izdano: (2025)

Supplementary Table S3 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma
od: Yuncheng Bei (16546095)
Izdano: (2025)

Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
od: Sheheryar Kabraji (15050565)
Izdano: (2025)

Supplementary Tables from Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
od: Santiago Duro-Sánchez (14959182)
Izdano: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
od: Martina S.J. McDermott (15206951)
Izdano: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
od: Srivandana Akshintala (16610490)
Izdano: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
od: Srivandana Akshintala (16610490)
Izdano: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Izdano: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Izdano: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Izdano: (2025)

Supplementary Table from Functional Analysis of <i>MET</i> Exon 14 Skipping Alteration in Cancer Invasion and Metastatic Dissemination
od: Feng Wang (44414)
Izdano: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
od: Xiaoqing Cheng (16918496)
Izdano: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
od: Katie E. Hebron (15046889)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3c48p9klsfa2hb3da5ds29a6be